All the news Showing 10 of 44 articles from: Genotype 3Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources US medical societies launch new hepatitis C treatment guidelines Liz Highleyman / 30 January 2014 The American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) and International Antiviral Society-USA (IAS-USA) yesterday announced the first new hepatitis C treatment guidelines ... Daclatasvir + sofosbuvir shows high hep C cure rate, new studies underway Liz Highleyman / 22 January 2014 A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of ... European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection Gilead press release / 17 January 2014 European Medicines Agency advises on compassionate use of daclatasvir European Medicines Agency / 26 November 2013 Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat Liz Highleyman / 14 November 2013 A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of people with genotype 2 hepatitis C treated for 12 weeks and 85% of people with genotype 3 ... FDA Panel Backs Sofosbuvir for Hepatitis C Medscape / 28 October 2013 Treating HCV genotypes 2 and 3 in HIV/HCV co-infected people Liz Highleyman / 10 October 2013 People co-infected with HIV and HCV, mostly with hepatitis C virus (HCV) genotype 3, responded about as well as HIV-negative people to interferon-based therapy after taking into account other factors associated ... Is 3 the New 1? Perspectives on Virology, Natural History and Treatment for Hepatitis C Genotype 3 Medscape (requires registration) / 08 October 2013 Summary from EASL 2013 for Hepatitis C - New HCV DAAs on their way soon: what do the phase III studies tell us? NATAP / 16 May 2013 Daclatasvir plus interferon-based therapy cures more genotype 2/3 hepatitis C patients Liz Highleyman / 07 May 2013 Adding the HCV NS5A inhibitor daclatasvir to pegylated interferon and ribavirin for 12 or 16 weeks led to higher response rates for previously untreated people with genotype 2 or 3 hepatitis C, ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive